Sponsored satellite symposia are not eligible for accreditation.
A Sponsored Symposium is an exclusive scheduled symposium session during the official program of the Congress. Only one Sponsored Symposium will be held between 12:30-14:30 daily on Tuesday, Wednesday, Thursday, and Friday in a room with a 2,000 person capacity. The program of the symposium is organized by the sponsor, including title and faculty, but is subject to approval by the Organizing Committee. (Available to Diamond and Platinum Patrons on first priority.)
Program By Date
Tuesday, June 9, 2015 12:30 – 14:30
Wednesday, June 10, 2015 12:30 – 14:30
Thursday, June 11, 2015 12:30 – 14:30
Friday, June 12, 2015 12:30 – 14:30
Advances in Aesthetic Medicine, sponsored by Merz
The past few decades have seen an increasing focus on a youthful appearance, resulting in an upswing in aesthetic products and procedures designed to reverse the aging process. Aesthetic clinicians have access to a large armamentarium to address patient objectives, including cosmeceuticals, energy-based devices, and injectable neuromodulators and soft tissue fillers. While each of these approaches addresses a specific aspect of rejuvenation or restoration, many patients require or request combinations treatment to achieve their goals.
A recent trend in aesthetic medicine is to use a combination of complimentary modalities to treat the multiple concerns of patients. This global approach addresses age-related changes on multiple levels and produces far more dramatic outcomes than those of any single modality, leading to improved patient satisfaction. To be able to provide this type of service, aesthetic practitioners need to keep up-to-date with evolving techniques and a broadening array of available products.
| Title: | Advances in Aesthetic Medicine: Contemporary Rejuvenation Options to Globally Mitigate the Aging Process |
| Date: | Wednesday, June 10, 2015 |
| Time: | 12:30 – 14:30 |
| Location: | Vancouver Convention Centre – East Hall A |
| Company: | Paradigm Medical Communications, LLC |
| Faculty/Speakers: | Diane S. Berson, MD, FAAD
Sabrina G. Fabi, MD, FAAD, FAACS Michael H. Gold, MD Michael A. C. Kane, MD |
| Objective: | This CME activity will provide an update of products and techniques in the areas of cosmeceuticals, energy-based aesthetic therapies, and aesthetic injectables, including information on evolving techniques and product indications, efficacy, and safety, with the goal of facilitating a global approach to rejuvenation. |
Improving patient management in rosacea: pathophysiological, psychosocial and clinical considerations, sponsored by Galderma
Rosacea is a multi-faceted disease, and effective treatment requires not only the management of a range of symptoms but also the consideration of aspects beyond clinical manifestations. This symposium discusses clinical symptoms in relation to underlying histopathology, alongside considering psychosocial aspects when defining individual treatment goals and differential treatment approaches. The 2015 Cochrane update on interventions in rosacea will be presented in addition to the pivotal clinical trials for ivermectin 10 mg/g cream for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients. The practical management of rosacea will be considered through real-life case studies and interactive discussion with the audience.
Click here for your invitation to this satellite symposium!
| Title: | Improving patient management in rosacea: pathophysiological, psychosocial and clinical considerations |
| Date: | Thursday, June 11, 2015 |
| Time: | 12:30 – 14:30 (Lunch boxes will be provided from 12:00) |
| Location: | Vancouver Convention Centre – East Hall A |
| Company: | Galderma |
| Faculty/Speakers: | Dr Jerry Tan, Canada
Dr Esther Van Zuuren, Netherlands Professor Bernard Cribier, France Dr Leon Kircik, USA Dr Alison Layton, UK Dr Adilson Costa, Brazil |
| Objectives: | The core objectives for the rosacea symposium are:
|
The Global Aesthetic Debate, sponsored by Galderma
An eminent faculty, including Prof. Monheit, Prof. Weiss, Dr. Levy, Dr. Meski, and Dr. Weinkle will be involving the audience in a dynamic debate to discuss new data from the Galderma Aesthetic & Corrective portfolio using live demonstrations, providing practical advice as well as patient management. The symposium is split into 2 sessions of 1 hour each, the second of which US physicians are kindly invited to attend. During the symposium, the faculty together with the audience will be examining innovation in practice; Emervel data, Restylane Perlane, Restylane Silk and addressing myths surrounding botulinum toxins. This will be a symposium with a difference.
Click here for your invitation to this satellite symposium!
| Title: | The Global Aesthetic Debate: The data, The detail, The difference |
| Date: | Friday, June 12, 2015 |
| Time: | 12:30 – 14:30 |
| Location: | Vancouver Convention Centre – East Hall A |
| Company: | Galderma |
| Faculty/Speakers: | Prof. Monheit
Prof. Weiss Dr. Levy Dr. Meski Dr. Weinkle |
| Objectives: |
|
New Frontiers and Treatment Advances for ATOPIC DERMATITIS (AD): Focus on the Immunopathobiology of AD and Role of Established Agents and Evolving Biologic Therapies for Optimizing Management in Patients with Moderate-to-Severe and Treatment-Resistant Atopic Dermatitis, supported by an Educational Grant from Sanofi and Regeneron Pharmaceuticals
This program focuses on optimizing the scientific understanding, advances, evaluation and management – including improved understanding of the pathoimmunobiology of AD and more consistent implementation of AAD guidelines – in patients with moderate-to-severe atopic dermatitis. The faculty will address guidelines, clinical trials focused on improving patient outcomes in patients with AD, immune-mediated mechanisms that play a role in the causation and perpetuation of skin lesions characteristic of AD, new translational dimensions of applying advances in biologic, established, and/or multimodal therapy of AD, and new evidence that provides a translational medicine-based rationale for consideration of biologic therapies in patients with moderate-to-severe AD.
| Title: | New Frontiers and Treatment Advances for ATOPIC DERMATITIS (AD): Focus on the Immunopathobiology of AD and Role of Established Agents and Evolving Biologic Therapies for Optimizing Management in Patients with Moderate-to-Severe and Treatment-Resistant Atopic Dermatitis |
| Date: | Tuesday, June 9, 2015 |
| Time: | 12:30 – 14:30 |
| Location: | Vancouver Convention Centre – East Hall A |
| Company: | Sanofi and Regeneron Pharmaceuticals |
| Faculty/Speakers: | Thomas Bieber, MD, PhD, MDRA – Program Chair Chair and Director Department of Dermatology and Allergology University of Bonn Bonn, Germany Mark Lebwohl, MD Eric Simpson, MD Emma Guttman, MD, PhD Amy S. Paller, MS, MD |
| Objective: | The program’s objective is to positively impact clinical behaviors, improve scientific and medical knowledge of emerging targets and therapies for moderate-to-severe AD with clinical promise, promote AAD-based guideline adherence for patients with AD, illuminate new and evolving, immune-based therapeutic strategies based on clinical trials and scientific advances that have the potential for improving clinical remissions in patients with moderate-to-severe AD; and review best practice benchmarks among dermatology specialists caring for patients with AD who are at high risk for resistant disease, severe disease, and/or treatment failures. |